Navigation Links
'Forrest Gump' mice show too much of a good thing, can be bad
Date:6/20/2013

A line of genetically modified mice that Western University scientists call "Forrest Gump" because, like the movie character, they can run far but they aren't smart, is furthering the understanding of a key neurotransmitter called acetylcholine (ACh). Marco Prado and his team at Robarts Research Institute say the mice show what happens when too much of this neurotransmitter becomes available in the brain. Boosting ACh is a therapeutic target for Alzheimer's disease because it's found in reduced amounts when there's cognitive failure. Prado's research is published in the Journal of Neuroscience.

"We wanted to know what happens if you have more of the gene which controls how much acetylcholine is secreted by neurons," says Prado, a Robarts scientist and professor in the Departments of Physiology and Pharmacology and Anatomy and Cell Biology at Western's Schulich School of Medicine & Dentistry. "The response was the complete opposite of what we expected. It's not a good thing. Acetylcholine release was increased threefold in these mice, which seemed to disturb cognitive function. But put them on a treadmill and they can run twice as far as normal mice before tiring. They're super-athletes." In addition to its function in modulating cognitive abilities, ACh drives muscle contraction which allowed for the marked improvement in motor endurance.

One of the tests the scientists, including first author Benjamin Kolisnyk, used is called the touch screen test for mice which uses technology similar to a tablet. After initiating the test, the mice have to scan five different spots on the touch screen to see a light flash, and then run and touch that area. If they get it right they get a reward. Compared to the control mice, the "Forrest Gump" mice failed miserably at the task. The researchers found the mice, which have the scientific name ChAT-ChR2-EYFP, had terrible attention spans, as well as dysfunction in working memory and spatial memory.

Prado interprets the research as showing ACh is very important for differentiating cues. So if your brain is presented with a lot of simultaneous information, it helps to pick what's important. But when you flood the brain with ACh, your brain loses the ability to discern what's relevant. This study was funded mainly by the Canadian Institutes of Health Research.


'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... -- Four US Biotech equities have been ... are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. ... and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ). ... are growing more bullish on the sector as a ... cash held overseas for tax reason by large US ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... SAN FRANCISCO, CA (PRWEB) , ... February 24, 2017 , ... ... awarding of a $224K grant from the National Institute of Mental Health (NIMH) for ... is based on Delpor’s PROZOR technology and is expected to deliver therapeutic ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
Breaking Biology Technology: